Research programme: KCNQ potassium channel agonists - Icagen, Inc.

Drug Profile

Research programme: KCNQ potassium channel agonists - Icagen, Inc.

Alternative Names: ICA-27243; ICA-69673

Latest Information Update: 08 Dec 2015

Price : $50

At a glance

  • Originator Icagen
  • Developer Icagen, Inc.
  • Class Analgesics; Antiepileptic drugs; Benzamides; Small molecules
  • Mechanism of Action KCNQ potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Epilepsy; Neuropathic pain

Most Recent Events

  • 12 Dec 2005 Data presented at the 35th Annual Meeting of the Society for Neuroscience (SfN-2005) have been added to the Epilepsy and seizure disorders, and Pain pharmacodynamics sections ,,
  • 21 Sep 2005 Data presented at the 230th American Chemical Society National Meeting (230th-ACS-2005) have been added to the Epilepsy and seizure disorders pharmacodynamics section
  • 13 May 2005 Preclinical trials still ongoing for Epilepsy and Neuropathic pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top